REDWOOD CITY, Calif. & BOSTON--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for ...
Analog Devices is at a turning point, with revenue and margin recovery underway after a challenging 2024, supported by broad-based growth across all segments in 2025. Analog Devices and Texas ...
REDWOOD CITY, Calif. & BOSTON--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for ...
一些您可能无法访问的结果已被隐去。
显示无法访问的结果